logo
Share SHARE
FONT-SIZE Plus   Neg

ISTA To Consider Revised Offer From Valeant - Update

Eye-disease drug developer ISTA Pharmaceuticals, Inc. (ISTA) Tuesday said it has received a revised non-binding proposal from Valeant Pharmaceuticals (VRX,VRX.TO) to acquire the company and would consider the updated proposal as part of its ongoing review of strategic options.

On December 16, 2011, ISTA had rejected a $6.50 per share hostile, non-binding bid made by Valeant, stating the offer undervalues the company and it sees a bright future, owing to its robust drug portfolio and a healthy pipeline.

In a meeting last week, Valeant raised its initial proposal to $7.50 per share in cash and set a target price of $8.50 per share in cash, subject to one week of due diligence. Valeant on Monday sent a letter to ISTA, confirming its increased non-binding proposal, which ISTA said included several inaccuracies about ISTA's process and the discussions between the two companies.

ISTA said its process for review of strategic options is advancing as planned in an expeditious manner. As part of the strategic review process revealed on December 16, 2011, ISTA is currently in talks with some parties interested in a strategic transaction.

The company said Valeant has not executed a confidentiality agreement and that if it chooses to execute a confidentiality agreement as other parties have done, ISTA would provide it the same non-public information provided to other parties.

Vicente Anido, Jr., President and Chief Executive Officer of ISTA, said, "Valeant has and continues to be offered the same confidentiality agreement, with no standstill provision, as all the other participants in our process and is subject to the same timeline...We do not think it is in the shareholders' best interest to abort our process to accommodate Valeant's artificially short timetable."

Greenhill & Co. is acting as financial advisor to ISTA. Stradling Yocca Carlson & Rauth and WilmerHale LLP are its legal advisors.

ISTA closed Friday at $7.27, down $0.09 or 1.22 percent, on 238,367 shares.

VRX settled lower by $0.19 at $48.19 on a volume of 2.19 million shares.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Editors Pick
AIG reported a plunge in second-quarter profit, hurt by a decline at its insurance business, debt-related losses and lower gains from the sale of investments. However, its earnings topped Street estimates, partly on contribution from aircraft leasing giant AerCap. AIG also announced a boost in dividend and said it would buyback an additional $5 billion stock. Automakers on Monday reported strong U.S. vehicle sales for the month of July, driven by continued demand for trucks and sport-utility vehicles amid an improving economy, lower gas prices and easy availability of credit. Detroit's Big Three - General Motors Co., Ford Motor Co. and FCA US, LLC - all reported vehicle sales above analyst expectations. British lender Lloyds Banking Group Plc. Friday reported higher profit in its first half, benefited by increased net interest income and margin as well as lower impairment. Looking ahead, the company lifted its net interest margin forecast.
comments powered by Disqus
Follow RTT